MET and neoplasm: As previously described, oncogenic alterations in ERBB2, FGFR, MET were found almost exclusively in the adenocarcinoma subtype (regardless of tumour location); On the other hand, EGFR and KRAS alterations as well as CCND1 amplification were found in tumours with both adenocarcinoma and squamous cell carcinoma histology.